Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Neuphoria Therapeutics Inc.NEUP · Entity 7639 | Director | January 20, 2026 | January 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Neuphoria Therapeutics Inc.
Report date January 20, 2026 · Filed January 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 15,550 |
Reported balance
After 2026-01-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-20 · Grant · Acquired 8,537 · Balance 15,550 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock.1. F2: The grant of RSUs is pursuant to the Company's Board of Directors annual remuneration policy. F3: Subject to the Reporting Person's continuous service to the Company through the first of the following dates: (a) the day prior to the Company' next annual shareholder meeting (which is expected to be no later than December 15, 2026) or (b) the effective date of a Change in Control of the Company, the RSUs shall fully vest. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock.1.
F2: The grant of RSUs is pursuant to the Company's Board of Directors annual remuneration policy.
F3: Subject to the Reporting Person's continuous service to the Company through the first of the following dates: (a) the day prior to the Company' next annual shareholder meeting (which is expected to be no later than December 15, 2026) or (b) the effective date of a Change in Control of the Company, the RSUs shall fully vest.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 20, 2026 Filed Jan 21, 2026 16:01 UTC | Neuphoria Therapeutics Inc. NEUP · Entity 7639 | GrantRestricted Stock Units · Derivative | 8,537 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-006170 · ownership.xml · derivative · entry 1 Ryan Jane · CIK 0002028936 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,550 Underlying: Common Stock · 8,537 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock.1. F2 · derivative.exercise_price: The grant of RSUs is pursuant to the Company's Board of Directors annual remuneration policy. F3 · derivative.exercise_date: Subject to the Reporting Person's continuous service to the Company through the first of the following dates: (a) the day prior to the Company' next annual shareholder meeting (which is expected to be no later than December 15, 2026) or (b) the effective date of a Change in Control of the Company, the RSUs shall fully vest. F3 · derivative.expiration_date: Subject to the Reporting Person's continuous service to the Company through the first of the following dates: (a) the day prior to the Company' next annual shareholder meeting (which is expected to be no later than December 15, 2026) or (b) the effective date of a Change in Control of the Company, the RSUs shall fully vest. Read SEC document |
| April 16, 2025 Filed Apr 18, 2025 08:02 UTC | Neuphoria Therapeutics Inc. NEUP · Entity 7639 | GrantRestricted Stock Units · Derivative | 6,783 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-033142 · ownership.xml · derivative · entry 1 Ryan Jane · CIK 0002028936 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,013 Underlying: Common Stock · 6,783 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock. F2 · derivative.exercise_date: Subject to the Reporting Person's continuous service to the Company through the day prior to the Company' next annual shareholder meeting (which is expected to be no later than November 30, 2025), the RSUs shall fully vest at 5:01 PM EST on the day prior to the Company's next annual shareholder meeting. F2 · derivative.expiration_date: Subject to the Reporting Person's continuous service to the Company through the day prior to the Company' next annual shareholder meeting (which is expected to be no later than November 30, 2025), the RSUs shall fully vest at 5:01 PM EST on the day prior to the Company's next annual shareholder meeting. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.